Free Trial
NASDAQ:PROC

Procaps Group (PROC) Stock Price, News & Analysis

Procaps Group logo
$1.78
-0.21 (-10.53%)
(As of 11/1/2024 ET)

About Procaps Group Stock (NASDAQ:PROC)

Key Stats

Today's Range
$1.77
$1.93
50-Day Range
$1.68
$2.24
52-Week Range
$1.68
$4.95
Volume
20,451 shs
Average Volume
12,303 shs
Market Capitalization
N/A
P/E Ratio
3.43
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Procaps Group Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
11th Percentile Overall Score

PROC MarketRank™: 

Procaps Group scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Procaps Group is 3.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.25.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Procaps Group is 3.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.56.

  • Read more about Procaps Group's valuation and earnings.
  • Percentage of Shares Shorted

    0.12% of the float of Procaps Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Procaps Group has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Procaps Group has recently increased by 11.62%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Procaps Group does not currently pay a dividend.

  • Dividend Growth

    Procaps Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.12% of the float of Procaps Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Procaps Group has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Procaps Group has recently increased by 11.62%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Procaps Group this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Procaps Group to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Procaps Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.90% of the stock of Procaps Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Procaps Group's insider trading history.
Receive PROC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Procaps Group and its competitors with MarketBeat's FREE daily newsletter.

PROC Stock News Headlines

Procaps Group’s Strategic Moves for Financial Stability
Procaps Group S.A. (PROC)
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
Procaps Issues Shareholder Letter Update
Procaps Group, S.A.: Procaps Issues Shareholder Letter Update
Procaps Issues Shareholder Letter Update
Procaps Issues Shareholder Letter
See More Headlines

PROC Stock Analysis - Frequently Asked Questions

Procaps Group's stock was trading at $4.07 on January 1st, 2024. Since then, PROC shares have decreased by 56.1% and is now trading at $1.7850.
View the best growth stocks for 2024 here
.

Procaps Group S.A. (NASDAQ:PROC) released its quarterly earnings data on Tuesday, December, 26th. The company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. The business had revenue of $118.41 million for the quarter, compared to the consensus estimate of $110.40 million.

Shares of PROC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Procaps Group investors own include PayPal (PYPL), Intuitive Surgical (ISRG), Adobe (ADBE), Baidu (BIDU), Cogent Communications (CCOI), Datadog (DDOG) and Illumina (ILMN).

Company Calendar

Last Earnings
12/26/2023
Today
11/02/2024
Next Earnings (Estimated)
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PROC
Fax
N/A
Employees
5,500
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$409.92 million
Cash Flow
$0.52 per share
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.16
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:PROC) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners